Abstract
Erectile dysfunction (ED) is a common medical condition that has a negative impact on men and their partners. The field has revolutionised over the last two decades and more treatment options are available now for the treatment of ED than ever before. Among available treatment options, the most commonly prescribed therapies are oral phosphodiesterase type 5 (PDE5) inhibitors. The first drug in this class, sildenafil citrate, generally provides patients and their partners with efficacious, safe, and discreet treatment that rapidly has become the first-line treatment option. Its successful introduction into clinical practice was soon followed by the launch of two other PDE5 inhibitors: tadalafil and vardenafil. The existence of these drugs has resulted in an increase in their marketing. However, the abundance of choices made the question “which PDE-5 inhibitor?” relevant for clinicians, patients and their partners. It is widely accepted that there are no significant differences in their safety and efficacy, a fact that has led to the initiation of studies aiming to evaluate them regarding patient preference. Nevertheless, the results are rather conflicting. Also a significant percentage of men initiating treatment switch between inhibitors or discontinue therapy. This article examines the peer-reviewed published data addressing patient ’ s preference and adherence to ED treatment with PDE5 inhibitors. It also examines strategies to improve compliance and satisfaction with treatment.
Keywords: PDE5 inhibitors, preference, adherence, cost, treatment optimization, education, treatment expectations
Current Pharmaceutical Design
Title: Phosphodiesterase Type 5 Inhibitors for the Management of Erectile Dysfunction: Preference and Adherence to Treatment
Volume: 15 Issue: 30
Author(s): T. F. Al-Shaiji and G. B. Brock
Affiliation:
Keywords: PDE5 inhibitors, preference, adherence, cost, treatment optimization, education, treatment expectations
Abstract: Erectile dysfunction (ED) is a common medical condition that has a negative impact on men and their partners. The field has revolutionised over the last two decades and more treatment options are available now for the treatment of ED than ever before. Among available treatment options, the most commonly prescribed therapies are oral phosphodiesterase type 5 (PDE5) inhibitors. The first drug in this class, sildenafil citrate, generally provides patients and their partners with efficacious, safe, and discreet treatment that rapidly has become the first-line treatment option. Its successful introduction into clinical practice was soon followed by the launch of two other PDE5 inhibitors: tadalafil and vardenafil. The existence of these drugs has resulted in an increase in their marketing. However, the abundance of choices made the question “which PDE-5 inhibitor?” relevant for clinicians, patients and their partners. It is widely accepted that there are no significant differences in their safety and efficacy, a fact that has led to the initiation of studies aiming to evaluate them regarding patient preference. Nevertheless, the results are rather conflicting. Also a significant percentage of men initiating treatment switch between inhibitors or discontinue therapy. This article examines the peer-reviewed published data addressing patient ’ s preference and adherence to ED treatment with PDE5 inhibitors. It also examines strategies to improve compliance and satisfaction with treatment.
Export Options
About this article
Cite this article as:
Al-Shaiji F. T. and Brock B. G., Phosphodiesterase Type 5 Inhibitors for the Management of Erectile Dysfunction: Preference and Adherence to Treatment, Current Pharmaceutical Design 2009; 15 (30) . https://dx.doi.org/10.2174/138161209789206944
DOI https://dx.doi.org/10.2174/138161209789206944 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Blockade of Diabetic Vascular Injury by Controlling of AGE-RAGE System
Current Drug Targets Hydrophilic Interaction Liquid Chromatography Tandem Mass Spectrometry: An Attractive and Prospective Method for Quantitative Bioanalysis in Drug Metabolism
Current Drug Metabolism Cortisol Regulation in the Metabolic Syndrome. A Novel Therapeutic Approach
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recent Advances in Obesity Pharmacotherapy
Current Clinical Pharmacology Lifestyle Changes and Surgical Treatment for Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Opening New Scenarios for Human MAO Inhibitors
Central Nervous System Agents in Medicinal Chemistry Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry Relationship Between Na<sup>+</sup>, K<sup>+</sup>-ATPase and NMDA Receptor at Central Synapses
Current Protein & Peptide Science Application of NKT Cells in Immunotherapy
Current Immunology Reviews (Discontinued) Cyclic AMP Enhancers and Aβ Oligomerization Blockers as Potential Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure
Current Vascular Pharmacology Management of Acute and Chronic Open Wounds: The Importance of Moist Environment in Optimal Wound Healing
Current Pharmaceutical Biotechnology Outcomes in Pregnant Patients with Subclinical Hypothyroidism and Thyroid Autoimmunity: A Critical Appraisal of Recent Randomized Controlled Trials
Endocrine, Metabolic & Immune Disorders - Drug Targets Pomegranate as a Possible Treatment in Reducing Risk of Developing Wound Healing, Obesity, Neurodegenerative Disorders, and Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Aquaretic Agents: Whats Beyond the Treatment of Hyponatremia?
Current Pharmaceutical Design Inhibitors of the TGF-β Superfamily and their Clinical Applications
Mini-Reviews in Medicinal Chemistry Antidiabetic Agents in Patients with Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: Metabolism and Clinical Practice
Current Drug Metabolism Beneficial Effects of the Mediterranean Diet on Metabolic Syndrome
Current Pharmaceutical Design Influence of Passion Fruit (Passiflora edulis, f. flavicarpa, DEG) Juice Sweetened with Sucrose, Saccharin and Cyclamate on Blood Glucose in Normal and Diabetic Rats (Rattus norvegicus)
The Natural Products Journal Prevention of Contrast Induced Nephropathy
Current Drug Therapy